Use of clopidogrel in the reduction of myocardial damage during percutaneous coronary intervention
Arijit Dasgupta, Debabrata MukherjeeGill Heart Institute, University of Kentucky, Lexington, KY, USAAbstract: It is estimated that approximately a quarter of patients undergoing coronary intervention may have significant post-procedural creatinine (CK)/creatinine kinase myocardial band (CK-MB) eleva...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2009-03-01
|
| Series: | Vascular Health and Risk Management |
| Online Access: | http://www.dovepress.com/use-of-clopidogrel-in-the-reduction-of-myocardial-damage-during-percut-a2983 |
| _version_ | 1818937419494326272 |
|---|---|
| author | Arijit Dasgupta Debabrata Mukherjee |
| author_facet | Arijit Dasgupta Debabrata Mukherjee |
| author_sort | Arijit Dasgupta |
| collection | DOAJ |
| description | Arijit Dasgupta, Debabrata MukherjeeGill Heart Institute, University of Kentucky, Lexington, KY, USAAbstract: It is estimated that approximately a quarter of patients undergoing coronary intervention may have significant post-procedural creatinine (CK)/creatinine kinase myocardial band (CK-MB) elevations and approximately half may have post-procedural troponin elevations. Current data suggest that periprocedural infarction is associated with short-, intermediate-, and long-term adverse outcomes, most notably mortality. This review examines the role of clopidogrel in decreasing periprocedural myonecrosis following percutaneous coronary intervention (PCI). Clopidogrel is an important pharmacologic agent used to reduce myocardial infarction post-coronary intervention as assessed directly by the evaluation of cardiac biomarkers and indirectly by the evaluation of short-term ischemic events. The optimal dose of clopidogrel is considered to be at least 300 mg given 6 to 15 hours prior to PCI but there is considerable evidence to suggest that a loading dose of 600 mg given 2 to 6 hours prior to PCI may be more efficacious in limiting post-coronary intervention events. The benefit obtained from clopidogrel appears independent of and incremental to that of other antiplatelet and antithrombotic agents used during and after coronary intervention.Keywords: percutaneous coronary intervention, myonecrosis, clopidogrel, antiplatelet agents, myocardial infarction  |
| first_indexed | 2024-12-20T05:51:40Z |
| format | Article |
| id | doaj.art-0b0d30be20db4ad88daf2074023e3116 |
| institution | Directory Open Access Journal |
| issn | 1176-6344 1178-2048 |
| language | English |
| last_indexed | 2024-12-20T05:51:40Z |
| publishDate | 2009-03-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Vascular Health and Risk Management |
| spelling | doaj.art-0b0d30be20db4ad88daf2074023e31162022-12-21T19:51:08ZengDove Medical PressVascular Health and Risk Management1176-63441178-20482009-03-012009default275286Use of clopidogrel in the reduction of myocardial damage during percutaneous coronary interventionArijit DasguptaDebabrata MukherjeeArijit Dasgupta, Debabrata MukherjeeGill Heart Institute, University of Kentucky, Lexington, KY, USAAbstract: It is estimated that approximately a quarter of patients undergoing coronary intervention may have significant post-procedural creatinine (CK)/creatinine kinase myocardial band (CK-MB) elevations and approximately half may have post-procedural troponin elevations. Current data suggest that periprocedural infarction is associated with short-, intermediate-, and long-term adverse outcomes, most notably mortality. This review examines the role of clopidogrel in decreasing periprocedural myonecrosis following percutaneous coronary intervention (PCI). Clopidogrel is an important pharmacologic agent used to reduce myocardial infarction post-coronary intervention as assessed directly by the evaluation of cardiac biomarkers and indirectly by the evaluation of short-term ischemic events. The optimal dose of clopidogrel is considered to be at least 300 mg given 6 to 15 hours prior to PCI but there is considerable evidence to suggest that a loading dose of 600 mg given 2 to 6 hours prior to PCI may be more efficacious in limiting post-coronary intervention events. The benefit obtained from clopidogrel appears independent of and incremental to that of other antiplatelet and antithrombotic agents used during and after coronary intervention.Keywords: percutaneous coronary intervention, myonecrosis, clopidogrel, antiplatelet agents, myocardial infarction http://www.dovepress.com/use-of-clopidogrel-in-the-reduction-of-myocardial-damage-during-percut-a2983 |
| spellingShingle | Arijit Dasgupta Debabrata Mukherjee Use of clopidogrel in the reduction of myocardial damage during percutaneous coronary intervention Vascular Health and Risk Management |
| title | Use of clopidogrel in the reduction of myocardial damage during percutaneous coronary intervention |
| title_full | Use of clopidogrel in the reduction of myocardial damage during percutaneous coronary intervention |
| title_fullStr | Use of clopidogrel in the reduction of myocardial damage during percutaneous coronary intervention |
| title_full_unstemmed | Use of clopidogrel in the reduction of myocardial damage during percutaneous coronary intervention |
| title_short | Use of clopidogrel in the reduction of myocardial damage during percutaneous coronary intervention |
| title_sort | use of clopidogrel in the reduction of myocardial damage during percutaneous coronary intervention |
| url | http://www.dovepress.com/use-of-clopidogrel-in-the-reduction-of-myocardial-damage-during-percut-a2983 |
| work_keys_str_mv | AT arijitdasgupta useofclopidogrelinthereductionofmyocardialdamageduringpercutaneouscoronaryintervention AT debabratamukherjee useofclopidogrelinthereductionofmyocardialdamageduringpercutaneouscoronaryintervention |